These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12038454)

  • 1. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
    Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
    Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.
    Salven P; Orpana A; Teerenhovi L; Joensuu H
    Blood; 2000 Dec; 96(12):3712-8. PubMed ID: 11090051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
    Pedersen LM; Klausen TW; Davidsen UH; Johnsen HE
    Ann Hematol; 2005 Aug; 84(8):510-6. PubMed ID: 15834569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
    Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
    Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.
    Salven P; Teerenhovi L; Joensuu H
    Blood; 1997 Oct; 90(8):3167-72. PubMed ID: 9376599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
    Bono P; Teerenhovi L; Joensuu H
    Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma.
    el-Far M; Fouda M; Yahya R; el-Baz H
    J Physiol Biochem; 2004 Dec; 60(4):253-8. PubMed ID: 15957243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Iijima K; Chizuka A
    Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
    Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
    Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
    Niitsu N; Sasaki K; Umeda M
    Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.
    Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY
    Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
    Ugurel S; Rappl G; Tilgen W; Reinhold U
    J Clin Oncol; 2001 Jan; 19(2):577-83. PubMed ID: 11208853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma.
    Gunsilius E; Petzer AL; Gastl G
    Br J Haematol; 2000 Mar; 108(3):661-3. PubMed ID: 10847704
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma.
    Aydin F; Yilmaz M; Ozdemir F; Kavgaci H; Yavuz MN; Yavuz AA
    Am J Clin Oncol; 2002 Dec; 25(6):570-2. PubMed ID: 12478000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients].
    Wróbel T; Mazur G; Usnarska-Zubkiewicz L; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Aug; 112(2):919-23. PubMed ID: 15675266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma.
    Huang SP; Wu MS; Wang HP; Yang CS; Kuo ML; Lin JT
    J Gastroenterol Hepatol; 2002 Nov; 17(11):1165-9. PubMed ID: 12453275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis.
    Yang J; Li W; He X; Zhang G; Yue L; Chai Y
    Dis Markers; 2015; 2015():786790. PubMed ID: 25810565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery.
    Karayiannakis AJ; Syrigos KN; Polychronidis A; Zbar A; Kouraklis G; Simopoulos C; Karatzas G
    Ann Surg; 2002 Jul; 236(1):37-42. PubMed ID: 12131083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.